Molecular Partners AG - Product Pipeline Review - 2015

Molecular Partners AG - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Molecular Partners AG - Product Pipeline Review - 2015’, provides an overview of the Molecular Partners AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Molecular Partners AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Molecular Partners AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Molecular Partners AG’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Molecular Partners AG’s pipeline products
Reasons to buy
  • Evaluate Molecular Partners AG’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Molecular Partners AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Molecular Partners AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Molecular Partners AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Molecular Partners AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Molecular Partners AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Molecular Partners AG Snapshot
Molecular Partners AG Overview
Key Information
Key Facts
Molecular Partners AG - Research and Development Overview
Key Therapeutic Areas
Molecular Partners AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Molecular Partners AG - Pipeline Products Glance
Molecular Partners AG - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Molecular Partners AG - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Molecular Partners AG - Drug Profiles
MP-0250
Product Description
Mechanism of Action
R&D Progress
MP-0274
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein 1 for Cancer
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein 2 for cancer
Product Description
Mechanism of Action
R&D Progress
Recombinant Proteins 1 for Ophthalmology
Product Description
Mechanism of Action
R&D Progress
Recombinant Proteins 2 for Ophthalmology
Product Description
Mechanism of Action
R&D Progress
Recombinant Proteins 3 for Ophthalmology
Product Description
Mechanism of Action
R&D Progress
Recombinant Proteins 4 for Opthalmology
Product Description
Mechanism of Action
R&D Progress
Recombinant Proteins 5 for Ophthalmology
Product Description
Mechanism of Action
R&D Progress
Molecular Partners AG - Pipeline Analysis
Molecular Partners AG - Pipeline Products by Target
Molecular Partners AG - Pipeline Products by Route of Administration
Molecular Partners AG - Pipeline Products by Molecule Type
Molecular Partners AG - Pipeline Products by Mechanism of Action
Molecular Partners AG - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Molecular Partners AG, Key Information
Molecular Partners AG, Key Facts
Molecular Partners AG - Pipeline by Indication, 2015
Molecular Partners AG - Pipeline by Stage of Development, 2015
Molecular Partners AG - Monotherapy Products in Pipeline, 2015
Molecular Partners AG - Out-Licensed Products in Pipeline, 2015
Molecular Partners AG - Out-Licensed Products/ Combination Treatment Modalities, 2015
Molecular Partners AG - Phase I, 2015
Molecular Partners AG - Preclinical, 2015
Molecular Partners AG - Discovery, 2015
Molecular Partners AG - Pipeline by Target, 2015
Molecular Partners AG - Pipeline by Route of Administration, 2015
Molecular Partners AG - Pipeline by Molecule Type, 2015
Molecular Partners AG - Pipeline Products by Mechanism of Action, 2015
List of Figures
Molecular Partners AG - Pipeline by Top 10 Indication, 2015
Molecular Partners AG - Pipeline by Stage of Development, 2015
Molecular Partners AG - Monotherapy Products in Pipeline, 2015
Molecular Partners AG - Out-Licensed Products in Pipeline, 2015
Molecular Partners AG - Pipeline by Top 10 Target, 2015
Molecular Partners AG - Pipeline by Top 10 Molecule Type, 2015
Molecular Partners AG - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook